Clonal evolution in chronic lymphocytic leukemia
Authors:
M. Brejcha 1; J. Mayer 2; D. Klodová 1; J. Sobotka 1; M. Wróbel 1; M. Doubek 2; Y. Brychtová 2; Š. Pospíšilová 2
Authors‘ workplace:
Kooperující pracoviště České leukemické skupiny – pro život (CELL , The CzEch Leukemia Study Group – for Life)
*; Hematologické oddělení, Onkologické centrum J. G. Mendela, Nový Jičín
1; Interní hematoonkologická klinika FN Brno
2
Published in:
Transfuze Hematol. dnes,15, 2009, No. 2, p. 103-106.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Chromosomal aberrations have important prognostic significance in patients with chronic lymphocytic leukemia. Aberrations detected by fluorescence in situ hybridization define specific subgroups that differ in the overall survival and the time from diagnosis to first treatment. Patients with deletion 17p appear resistant to standard chemotherapy regimens and detection of this cytogenetic abnormality may influence therapeutic decisions. Because additional genetic defects (clonal evolution) may be acquired during the course of the disease, cytogenetic analysis is recommended not only at diagnosis, but prior every line of the treatment.
Key words:
chronic lymphocytic leukemia, chromosomal aberations, clonal evolution
Sources
1. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198–206.
3. Mayer J, Schwarz J, Doubek M, et al. Co nám v každodenní praxi skutečně říkají tzv. moderní prognostické faktory u chronické lymfatické leukemie? Transf Hemat dnes 2007; 13: 106–116.
4. Papajík T, Jarošová M, Pikalová Z, Indrák K. B-chronická lymfatická leukemie. Část II: Diagnostická kritéria a význam stavení individuální prognózy nemocného. Transfuze Hemat dnes 2006; 12: 132–139.
5. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910–1916.
6. Kröber A, Seiler T, Benner A, et al. V(H) station status, CD38 expression level, genomic abberations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410–1416.
7. Dicker F, Schnittger S, Haferlach T, Kern W, Schoch C. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood 2006; 108: 3152–3160.
8. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442–2451.
9. Mayr C, Speicher MR, Kofler DM, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742–751.
10. Hallek M., Cheson BD, Katovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International workshop on chronic lymphocytic leukemia updating the National Cancer Institute–Working Group 1996 guidelines, Blood 2008; 111: 5446–5456.
11. Juliusson G, Oscier DG, Fitchett M, et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720–724.
12. Döhner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensit nodal involvement and inferior prognosis. Blood 1997; 89: 2516–2522.
13. Döhner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580–1589.
14. Oscier D, Fitchett M, Hergert T, Lambert R. Karyotypic evolution in B-cell chronic lymphocytic leukaemia. Genes, Chromosomes & Cancer 1991; 3: 16–20.
15. Juliusson G, Friberg K, Gahrton G. Consistency of chromosomal aberrations in chronic B-lymphocytic leukemia. Cancer 1988; 62: 500–506.
16. Nowell PC, Moreau L, Growney P, Besa EC. Karyotypic stability in chronic B-cell leukemia. Cancer Genet Cytogenet 1988; 33: 155–160.
17. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. Karyotypic evolution in CLL: Identification of a new sub-group of patients with deletions of 11q and advanced or progressive disease. Leukemia 1995; 9: 2003–2008.
18. Finn WG, Kay NE, Kroft SH, Church S, Peterson LC. Secondary abnormalities of chromosome 6q in B-cell chronic lymphocytic leukemia: A sequential study of karyotypic instability in 51 patients. Am J Hematol 1998; 59: 223–229.
19. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634–4641.
20. Shanafelt TD, Hanson C, Dewald GW, et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patiens with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 2008; 26(14): e5–e6.
21. Stilgenbauer S, Sander S, Bullinger L, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistence to therapy, and short survival. Haematologica 2007; 92: 1242–1245.
22. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of difuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.
23. Fält S, Merup M, Gahrton G, Lambert B., Wennborg A. Identification of progression markers in B-CLL by gene expression profiling. Exp Hematol 2005; 33: 883–893.
24. Fernandez V, Jares P, Salaverria I, et al. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica 2008; 93: 132–136.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 2
Most read in this issue
- Microchimerism – on the edge of incipient AML relapse?
- Clonal evolution in chronic lymphocytic leukemia
- Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic
- Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome